Respiratory Syncytial Virus (RSV) Therapeutics Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Apr 2018| TMR505A| Transparency

Report Highlights

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Overview

Respiratory syncytial virus infection is highly contagious. It is reported to be the most common cause of pneumonia and bronchiolitis in children as well as adults. According to the Center for Disease and Prevention, around 25-40 of every 100 children exposed to RSV infection for the first time develop signs of bronchiolitis or pneumonia. No approved drugs have been available in the market to treat RSV infection till date, and only prophylaxis drugs have been used. Therefore, several biopharmaceutical companies are investing in research and development in order to develop new drugs and vaccine to treat or prevent the RSV infection.

The global respiratory syncytial virus (RSV) therapeutics market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on drugs type, dosage form, distribution channel, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. Additionally, the section comprises competitive matrix and company profiles with business overview in order to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global respiratory syncytial virus (RSV) therapeutics market.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Key Segments

Based on drugs type, the global respiratory syncytial virus (RSV) therapeutics market can be segmented into palivizumab, ribavirin, and others. The drug type segments have been analyzed based on type of drug uses to treat RSV infection in the different region. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. According to dosage form, the global respiratory syncytial virus (RSV) therapeutics market can be classified into oral, injectable, and others. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Respiratory Syncytial Virus (RSV) Therapeutics Market: Regional Outlook

In terms of geography, the global respiratory syncytial virus (RSV) therapeutics market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain and Rest of Europe), Asia Pacific (China, Japan, India, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico and Rest of Latin America) and Middle East and Africa (GCC Countries, South Africa, Israel, and Rest of MEA). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the respiratory syncytial virus (RSV) therapeutics market are include F. Hoffmann-La Roche Ltd., AstraZeneca plc, Merck & Co., Inc., AbbVie, Inc., Valeant Pharmaceuticals International, Inc, GlaxoSmithKline plc., ReViral Ltd., Gilead Sciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global respiratory syncytial virus (RSV) therapeutics market has been segmented as follows:

Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drugs Type

Palivizumab
Ribavirin
Others
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form

Oral
Injectable
Others
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel

Drug Stores and Retail Pharmacies
Hospital Pharmacies
Others
Respiratory Syncytial Virus (RSV) Therapeutics Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
Japan
China
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

  • Table 1 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type/Vaccine, 2015–2025
  • Table 2 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form 2015–2025
  • Table 3 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel 2015–2025
  • Table 4 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
  • Table 5 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
  • Table 6 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
  • Table 7 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
  • Table 8 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 9 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/ Sub-Region, 2015–2025
  • Table 10 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
  • Table 11 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
  • Table 12 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 13 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
  • Table 14 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
  • Table 15 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
  • Table 16 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 17 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2015–2025
  • Table 18 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
  • Table 19 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
  • Table 20 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
  • Table 21 : Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub Region, 2015–2025
  • Table 22 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drugs Type, 2015–2025
  • Table 23 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2015–2025
  • Table 24 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025a
  • Figure 1 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2025
  • Figure 2 : Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Type of Drugs/Vaccine (2016)
  • Figure 3 : Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Dosage Form (2016)
  • Figure 4 : Global Respiratory Syncytial virus (RSV) Therapeutics Market Value Share, by Distribution Channel (2016)
  • Figure 5 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Drug Type/Vaccine, 2016 and 2025
  • Figure 6 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Palivizumab, 2015–2025
  • Figure 7 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Ribavirin, 2015–2025
  • Figure 8 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Drug Type/Vaccine: Others, 2015–2025
  • Figure 9 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type/Vaccine, 2017–2025
  • Figure 10 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Dosage Form, 2016 and 2025
  • Figure 11 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Oral, 2015–2025
  • Figure 12 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Injectable, 2015–2025
  • Figure 13 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Dosage Form: Others, 2015–2025
  • Figure 14 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Dosage Form, 2017–2025
  • Figure 15 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market, by Distribution Channel, 2016 and 2025
  • Figure 16 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Drug Stores and Retail Pharmacies, 2015–2025
  • Figure 17 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Hospital Pharmacies 2015–2025
  • Figure 18 : Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Distribution Channel: Others, 2015–2025
  • Figure 19 : Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Distribution Channel, 2017–2025
  • Figure 20 : Global Respiratory syncytial virus (RSV) Therapeutics Market Value Share, by Region, 2016 and 2025
  • Figure 21 : Respiratory Syncytial virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2016–2024
  • Figure 22 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
  • Figure 23 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2017 and 2025
  • Figure 24 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
  • Figure 25 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 26 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
  • Figure 27 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 28 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
  • Figure 29 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 30 : North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 31 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
  • Figure 32 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub-Region, 2016 and 2025
  • Figure 33 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub-Region, 2017–2025
  • Figure 34 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 35 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
  • Figure 36 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 37 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
  • Figure 38 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 39 : Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 40 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
  • Figure 41 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
  • Figure 42 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
  • Figure 43 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 44 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
  • Figure 45 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 46 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
  • Figure 47 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 48 : Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 49 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
  • Figure 50 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country, 2016 and 2025
  • Figure 51 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country, 2017–2025
  • Figure 52 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 53 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drug Type, 2017–2025
  • Figure 54 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 55 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
  • Figure 56 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 57 : Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 58 : Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
  • Figure 59 : Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Country/Sub Region, 2016 and 2025
  • Figure 60 : Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Country/Sub Region, 2017–2025
  • Figure 61 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2016 and 2025
  • Figure 62 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness, by Drugs Type, 2017–2025
  • Figure 63 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, Dosage Form, 2016 and 2025
  • Figure 64 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, Dosage Form, 2017–2025
  • Figure 65 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2016 and 2025
  • Figure 66 : Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
  • Figure 67 : Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 68 : R&D Intensity (US$ Bn), 2015–2016
  • Figure 69 : Breakdown of Net Sales of Diabetes Care Business Area, by Region 2016
  • Figure 70 : Breakdown of Net Sales, by Diagnostic Division, 2016
  • Figure 71 : Breakdown of Net Sales, by Region, 2017 (%)
  • Figure 72 : R&D Intensity and Sales & Marketing Intensity – Company Level, (US$ Bn), 2016–2017
  • Figure 73 : Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
  • Figure 74 : Breakdown of Net Sales, (by Business Segment), 2017
  • Figure 75 : Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
  • Figure 76 : R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
  • Figure 77 : Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 78 : Breakdown of Net Sales, (Overall Company Level), 2016
  • Figure 79 : Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
  • Figure 80 : Breakdown of Net Sales, by Region, 2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS